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Abstract: Widespread screening with prostate-specific antigen (PSA) has led to a signifi-
cant increase in the detection of early stage, clinically localized prostate cancer (CaP). Vari-
ous  treatment options for localized CaP are discussed in this review article including active 
 surveillance, radical prostatectomy, radiation therapy, and cyrotherapy. The paucity of high-level 
evidence adds a considerable amount of controversy when choosing the “optimal”  intervention, 
for both the treating physician and the patient. The long time course of CaP intervention  outcomes, 
combined with continuing modifications in treatments, further complicate the  matter. Lacking 
randomized trials that compare treatment options, this review article attempts to summarize 
the different treatment options and associated side-effects, including effects on health-related 
quality of life, from current published literature.
Keywords: prostate cancer, PSA, detection
Introduction
One of the major challenges in caring for men with newly diagnosed prostate cancer 
(CaP) is deciding between the many treatment options available. Often, a patient with 
newly diagnosed localized CaP seeks the “right” answer from his treating physicians. 
In fact, short of encouraging participation in clinical trials, it is difficult to define 
the “optimal” way to treat localized CaP. Currently, the treatment of localized CaP 
remains controversial. This controversy is highlighted by a recent specialist survey on 
the “optimal” treatment of a hypothetical patient with localized CaP: approximately 
29% favored expectant management, 33% favored radiotherapy and 39% chose radical 
prostatectomy.1 The lack of consensus amongst experts underscores how important 
it is for men diagnosed with CaP to make an informed treatment decision through an 
objective discussion of the risks and benefits of each approach. In planning a treatment, 
the burden typically falls upon the primary diagnosing physician, most commonly 
the urologist, to discuss with the patient both the choice of intervention and also the 
concerns of quality of life and longevity. Each treatment often carries unique potential 
for side effects, variable long term cancer control data. The long time course of CaP 
intervention outcomes combined with continuing modifications in treatments further 
complicate the matter.
This article will discuss surgical and nonsurgical options available for the treatment 
of newly diagnosed localized CaP and will highlight some of the advances in each 
area. For patients with low-volume and low-grade cancer, characteristics typically 
associated with minimal risk of cancer progression, a considerable controversy exists 
regarding the optimal treatment, including whether to treat at all. Finding the right 
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approach for treating high risk CaP is also difficult. However, 
while monotherapy with radical prostatectomy or radiation 
may be adequate for some men, there are randomized trials 
suggesting the need for a multi-modal approach to a more 
aggressive high risk cancer.
Risk stratification
D’Amico and colleagues developed the concept of risk 
stratification, allowing the classification of men into low-, 
intermediate-, and high-risk pretreatment groups using 
a combination of clinical data: prostate-specific antigen 
(PSA), Gleason sum, and clinical stage (Table 1).2 The 
classification was originally developed to estimate the risk 
of biochemical recurrence following treatment for localized 
CaP and has become an important component in treatment 
 recommendations. Other methods such as the Partin tables 
or Kattan nomograms may help guide therapy as they 
suggest the probability of organ confined disease or if the 
cancer has spread outside the prostate.3 In the current era of 
 multimodality therapy, this data may help guide  treatment 
choices as well as create realistic expectations on the 
 probability that a single treatment would be successful or if 
a combined approach is likely to be necessary.
Additional patient specific data may aid in  determining 
the aggressiveness of CaP and guide recommendations 
towards the best treatment option. For example, a rise of 
PSA . 2.0 ng/mL/year before radical prostatectomy was a 
predictor for CaP mortality with a 15% CaP mortality rate 
at 7 years. No patients with a PSA rise of ,2.0 ng/mL/year 
before surgery died from CaP. This rise of .2.0 ng/mL/year 
identifies a group of patients with aggressive and potentially 
life threatening CaP.4 A PSA density .0.15 ng/mL/cm3 
predicted those more likely to receive active treatment after 
active surveillance (AS).5 These studies suggest that clinical 
data including PSA kinetics may identify patients at elevated 
risk of disease progression and have a potential role in patient 
counseling in favor or against specific therapy.
Active surveillance and watchful waiting
Growing in popularity are “treatment” approaches for 
localized, asymptomatic CaP that do not involve an active 
intervention: active surveillance and watchful waiting (WW). 
While similar, there are distinct differences. Watchful waiting 
is now considered the intent to treat only if, or when, metas-
tases or symptomatic progression appears. This is usually 
 limited to asymptomatic men with limited life expectancy 
who often have high grade tumors. Contemporary AS proto-
cols aim to treat, with curative intent, those prostate cancers 
that develop more aggressive features during a period of 
surveillance and while the CaP is still amenable to definitive 
therapy such as surgery or radiotherapy. While there is no 
uniform consensus at present, AS generally involves periodic 
follow up examinations, PSA testing and repeat biopsy.
Advocates of AS argue that CaP is over treated in the 
United States. There is a glaring discrepancy between the 
number of patients diagnosed with CaP and the number of men 
that will die from this disease. There is a 16% lifetime risk of 
being diagnosed with CaP but only a 3% lifetime risk of dying 
from it.6 Autopsy data shows that despite the  presence of CaP 
in one-third of men over age 60 and up to 50% of men over 
70, men in the United States are more likely to die of other 
comorbid conditions.7 Knowledge of the  natural history of 
low-risk CaP has also improved. Parker, et al  estimated that 
the 15-year CaP specific  mortality for conservative manage-
ment of screen detected CaP was 0%–2% if the Gleason score 
were ,7.8 Data from the recently completed European Ran-
domized Study of Screening for Prostate Cancer, estimated 
the lead time associated with PSA screening to be 10.3 years 
and the over diagnosis rate to be 54%.9 These studies highlight 
the need to identify more definitive factors to distinguish 
insignificant disease from that which will result in disease 
specific morbidity and mortality.
One of the challenges of an AS protocol is the concern 
of under sampling and inadequate mapping of the volume 
of cancer present. An AS study from MD Anderson Cancer 
Center demonstrated very low upstaging at the time of 
prostatectomy and that all specimens had organ confined 
tumor. The transition zone was involved in 29% of unifocal 
and 71% of multifocal tumors.10 Therefore when instituting 
an AS program, a repeat biopsy is usually recommended. 
Despite these findings, van den Bergh et al have shown that 
delayed intervention within 2 years does not have worse 
pathologic features compared to patients who undergo 
immediate radical prostatectomy.11 Only a small percentage 
of patients on AS will show signs of disease progression, 
with an estimated risk of metastasis of ,1% at 2 to 8 years 
while on surveillance.11,12,13 Also, patients with low-risk 
 features (PSA , 10 ng/mL, clinical stage T1–T2a, and biopsy 
 Gleason sum 6 or less) who select AS have an estimated 
disease-specific mortality of 1% at 8 years.14 (See Table 2)
Table 1  D’Amico risk stratification of prostate cancer2
PSA ng/mL Gleason sum Clinical stage
Low risk #10 #6 #T2a
Intermediate risk 10–20 7 T2b
High risk $20 8–10 $T2c
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If a patient progresses on an AS protocol, early  intervention 
can be offered. As noted, delayed intervention does not appear 
to significantly compromise successful outcomes compared to 
immediate intervention. Several other studies have also dem-
onstrated that low-risk patients who delayed prostatectomy for 
medians of 6 and 22 months did not experience more adverse 
pathologic outcomes nor a compromised curability.15,16 
Patients need to be counseled that AS, as the name implies, 
is an active approach to  following cancer and to reassure 
them that, if their tumor shows any sign of biochemical or 
pathologic progression during follow-up, intervention can be 
undertaken safely at that time with minimal added risk.
AS allows close follow-up of disease and intervention 
with curative intent triggered by early signs of disease 
 progression. An accepted definition of suitable candidates 
for AS has been offered by Epstein and associates. Based on 
the Hopkins radical prostatectomy experience, preoperative 
parameters were assessed to predict which patients were 
likely to harbor cancers with low risk, favorable features. 
A PSA density (PSAD) , 0.15 ng/mL, clinical stage T2a 
or less, and no biopsy Gleason grade 4 or 5 led to a 73% 
predictive accuracy for favorable disease.17 The AS  strategy 
is appropriate for patients who have a life expectancy of 
less than 10 years and for healthy men 65 years of age or 
older who have low-volume, low-grade CaP as noted by 
Epstein.18 This approach avoids the potential complications of 
definitive therapy. From a quality of life standpoint, possible 
adverse effects of AS include increased anxiety and patient 
Table 2 Preliminary outcomes of active surveillance
Author Eligibility criteria Criteria for intervention Median age Median  
follow-up
DSS
Dall-era, et al13 T1–1, GS # 6,  
PSA ,10 ng/mL  
% positive cores ,33%
GS $ 7, increase  
PSA or tumor volume
63 yrs 43 mos 100%
Klotz14 T1c–T2a, GS # 6,  
PSA # 10 ng/mL
PSADT # 3yrs,  
PSA . 10 ng/mL,  
PSAv 2 ng/mL/yr
70 yrs 72 mos 99%
Abbreviations: PSA, prostate specific antigen; GS, gleason score; PSADT, PSA doubling time; PSAV, PSA velocity; DSS, disease specific survival.
Follow-up 
PSA, DRE q3 mos
x 2yrs, then q6 mos
Biopsy at 1yr, and
then q3 to 5yrs
Intervention 
Eligibility 
PSA <10
Gleason §6
cT1c-cT2a
Active
surveillance 
key points
•
•
•
•
Grade increase to
Gleason 7
PSA doubling time 
<3yrs
•
•
•
Figure 1 Summary of active surveillance.
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 compliance with repeated prostate biopsies. Clinical progres-
sion and loss of the opportunity for definitive “cure”, while 
rare in properly selected men, remains a concern. Patient 
eligibility into active surveillance, subsequent follow-up, and 
when to intervene is summarized in Figure 1.
Radical prostatectomy
One very clear advantage of radical prostatectomy (RP) 
over other treatment options is precise pathologic staging. 
As noted, prostate needle biopsy is not entirely accurate, 
and therefore non-surgical treatment decisions are often 
made based on Partin or Kattan nomograms. At times, these 
nomograms may under stage the extent of CaP. For example, 
extracapsular extension (ECE) has been found in up to 15% 
of patients with presumed low risk organ-confined disease. 
In addition, roughly a third of the patients undergoing 
 prostatectomy will experience a significant upgrade of their 
Gleason score (upstaging of pattern Gleason 3 to a diagnosis 
of pattern Gleason 4 or 5).19 Following RP, a urologist has 
clear pathologic data on determining whether the local  cancer 
has been removed, and reassure the patient of a 10-year 
disease-free survival of well above 90%.20
From a quality of life concern, RP provides the added 
benefit of an unambiguous interpretation of post-operative 
PSA, so that a patient can often be reasonably assured that his 
cancer was removed based on an “undetectable” PSA level 
(standard PSA assay of ,0.2 ng/mL). If the patient’s disease 
is upstaged to pathologic T3 or T4 disease after RP, the patient 
can be counseled on the use of adjuvant radiation therapy in 
a timely fashion, which has been shown to reduce the risk of 
metastasis and improve overall survival.21,22 In addition, an 
inability to achieve an undetectable PSA or a PSA recurrence 
following RP (PSA . 0.2 ng/mL), allows for early therapy 
in a salvage or an adjuvant fashion. Boorjian et al showed 
that adjuvant radiotherapy was associated with significantly 
improved 10-year biochemical recurrence-free survival, 
local recurrence-free survival and a decreased need for late 
hormone therapy.23 Also, in patients who received salvage 
radiation, the risk of local recurrence was decreased and 
systemic progression and hormonal therapy was delayed.
Once again, there is a paucity of clinical trials comparing 
radical to other treatment modalities. The American College of 
Surgeons Oncology Group attempted a trial that randomized 
low risk men between brachytherapy and radical prostatec-
tomy. Due to very poor accrual, the trial was never completed.24 
One prospective randomized trial has shown a distinct survival 
advantage of RP over watchful waiting. At 12 years, 12.5% 
of the surgery group and 17.9% of the watchful waiting group 
had died of CaP, and at 12 years, 19.3% of men in the surgery 
group and 26% of men in the watchful waiting group had been 
diagnosed with distant metastases.25 A  retrospective cohort 
analysis compared oncologic cure rates for RP, external beam 
radiation therapy (EBRT) and brachytherapy in low-risk CaP. 
Follow-up of up to 8 years after therapy showed a significant 
PSA failure-free survival advantage for RP over EBRT (88% 
vs 78%). However, the study has been criticized, as the 
EBRT patients received on average RT dose of 70 Gy, which 
is currently considered a low dose, as dose escalation above 
this level has shown to improve biochemical disease specific 
survival.26 Regardless, long term outcomes after RP are strong 
with RP considered by most to be the “gold standard” in the 
treatment of localized CaP.
A recent multi-institutional study of prostate cancer 
specific mortality (PCSM) after RP at 15 years was 12%.27 
Results from this study helped establish a nomogram that 
predicts that only 4% in the modern PSA era of contemporary 
patients, had a predicted 15-year PCSM of greater than 5%. 
The authors concluded that few patients will die from CaP 
within 15 years of radical prostatectomy, even with adverse 
clinical features.28
Excellent outcomes after RP have been reported in older 
men as well. In patients .70 years of age, 10-year cancer-
specific survival rates for low, intermediate and high risk 
were 99.5%, 97.5% and 94%, respectively.28 Postoperative 
complications in men aged 70–74 years were comparable 
to the younger cohort of men aged 65–69 years. The rate of 
complications was only slightly higher in patients 75 years and 
older. Outcome of RP is related much more to the  preoperative 
comorbidity than to age alone.29 A life  expectancy .10 years 
is the most frequently used benchmark for prostatectomy as 
definitive therapy for patients with localized CaP.30
With its introduction over a decade ago, laparoscopic radical 
prostatectomy (LRP) challenged the standard  retropubic and 
perineal approaches. LRP has been criticized for its difficult 
learning curve and its long operating times, allowing only limited 
centers of excellence to  perform this technically demanding 
operation. Robotic-assisted technology has further allowed 
the transition of the LRP into the robotically assisted radical 
prostatectomy RARP.31 Now nine years after its approval by 
the FDA, sixty-three percent of Tier I hospitals own a daVinci 
surgical system, and the robotic approach accounted for 81% of 
all prostate-removal procedures in the US last year.32
There are several potential advantages of the robotic 
approach. RARP is associated with decreased blood loss, 
and a shorter hospital stay. RARP also appears to afford 
faster convalescence when compared to the RP, while still 
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achieving similar oncologic outcomes.33 Although, long term 
oncologic data is not available yet with RARP, there are 
numerous series evaluating positive margin rate (PSM), an 
independent predictive factor for biochemical recurrence. In a 
review of a comparison of matched-pair analysis of open RP 
versus RARP, no difference in the PSM rates between RARP 
and open RP was noted, and the intermediate biochemical 
progression-free survival was also not significantly different.34 
By contrast with these results, in a cumulative analysis of six 
comparative studies reporting data on margins, Ficarra et al 
showed a statistically significant difference in favor of RARP 
over open RP.20 A recent multicenter analysis published in 
JAMA reviewed the outcomes of about 2,000 men treated 
with minimally invasive surgical techniques from 2003 to 
2007.35 They were compared with approximately 6,900 men 
who had standard open radical prostatectomy. The minimally 
invasive surgical group had shorter hospital stays and fewer 
immediate surgical complications compared with open 
surgery. However, 18 months post operatively, there was a 
greater risk of incontinence and erectile dysfunction in com-
parison to the open surgery group. When adjusted for both 
patient and tumor characteristics, men in both groups required 
similar amounts of adjuvant therapy. Additional long term 
studies will be necessary if the claims of improved outcomes 
of minimally invasive surgery for CaP will be validated.
As more surgeons learn and perform RARP, it is likely that 
further modifications will be made at improving outcomes. 
Kaouk et al have described using laparo-endoscopic single-site 
surgery (LESS) to perform RP. This technique is performed via 
a single umbilical incision, with all instruments used through 
the single site. This is illustrative of the recent shift in surgery 
to more even more minimally invasive approaches.36
Lastly, a comment should be made concerning the major 
shift in the management of node positive CaP at the time of 
radical prostatectomy. Although the classic teaching is that 
the procedure should be abandoned in the setting of lymph 
node involvement, recent data including prospective clinical 
trials and retrospective analysis suggests that this is no longer 
considered proper management.37,38 Overall survival may 
in fact be improved with the removal of both the prostate, 
lymph nodes and the immediate use of hormonal therapy.38 
Data from Messing et al also suggests that a subset of men 
with positive nodes may have long term disease free survival 
without additional hormonal therapy.37
In conclusion, in order to fully counsel a patient about which 
surgical modality to choose with regards to  complications, onco-
logic and functional outcomes, a large randomized  controlled 
trial comparing open vs laparoscopic vs  robotic-assisted 
 prostatectomy are required but none are currently planned. One 
factor that has been shown to improve both the cancer control 
and functional results of radical prostatectomy is the experience 
of the surgeon, regardless of the technique.39
Radiation therapy
The field of radiation oncology for the treatment of localized 
CaP is constantly being reevaluated to optimize delivery 
and optimize cancer control but also to minimize  damage 
to surrounding normal tissues. Development of better 
 cancer-targeting therapies in the form of three-dimensional 
conformal radiation therapy (3DCRT) and intensity- modulated 
radiotherapy (IMRT) and the use of image guided (IGRT) 
techniques such as fiducial markers theoretically decrease 
the side effects seen with EBRT.40 Similarly,  during this 
same time frame, other advances in the field have  supported 
the use of higher doses of radiation for  organ-confined disease 
and the use of androgen deprivation therapy (ADT) concurrent 
with EBRT with higher risk tumors.
Data from retrospective analyses suggest that the noted 
technical improvements translate into decreased rates of 
local failure and distant metastases, as well as better overall 
survival. An example of these findings is shown in an analysis 
of 1,465 men treated in four randomized trials conducted by 
the Radiation Therapy Oncology Group (RTOG). Radiation 
doses .66 Gy were associated with a 29% lower relative 
risk of death from CaP compared to lower doses.41 It is clear 
that for the treatment of intermediate to high-risk CaP with 
radiotherapy high doses are needed for high tumor control. 
In randomized studies of low dose compared to high dose, 
a better biochemical control, expressed as PSA-control, was 
found in favor of the high-dose groups.42,43 Multiple trials have 
demonstrated that doses of 78 to 80 Gy are needed to obtain 
definitive therapy for CaP, which is a great increase from the 
70 to 74 Gy that was previously the standard of care.43,44 As the 
technology to deliver more accurate RT develops even higher 
radiation doses are being considered. The RTOG 0126, a large 
randomized dose escalation trial to look at doses in excess of 
81 Gy, recently completed accrual.45 Given the fact that dose 
escalation of RT has shown a survival benefit for men, there 
is optimism that further dose escalation may benefit patients 
with high-risk localized disease. Although it is feasible to 
administer doses in excess of 81 Gy using these techniques, 
whether doses above 78 Gy provide added benefit for men 
with low-risk disease remains controversial.
The use of RT in combination with ADT for CaP patients is 
clearly supported by multiple randomized trials.46,47  However, sev-
eral questions remain unanswered, including the optimal sequenc-
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ing and duration of androgen deprivation. In the RTOG 8610, 
471 men were randomly assigned to RT with or without Zoladex 
plus flutamide. ADT was administered for 2 months before and 
2 months during RT. At a median follow-up of 12.5 years, ADT 
significantly decreased the rates of disease-specific mortality, 
distant metastases, and biochemical failure (23% vs 36%, 35% 
vs 47%, and 65% vs 80% with and without ADT, respectively) 
while increasing the rate of disease-free survival (11% vs 3%).48 
D’Amico et al reported a survival benefit with neoadjuvant 
(NADT) of 6 months in patients with intermediate risk CaP.47 The 
major endpoint of the study was overall survival and the time to 
PSA . 1.0 ng/mL and an increase in the PSA by .0.2 ng/mL 
on two consecutive occasions. Patients randomized to receive 
NADT had a significantly improvement in overall survival, cause 
specific survival and survival without salvage ADT. One draw-
back in these studies is that the dose of RT delivered would be 
considered suboptimal by today’s standards, and therefore would 
ADT provide benefit in current patients receiving higher radiation 
doses? Therefore, some investigators have argued that if adequate 
local doses are given ADT may not be required.49
Another area of advancement has been with the use of 
prostate markers to allow for an accurate guide in delivering 
RT. Our experience from the Kimmel Cancer Center has shown 
that placement of gold fiducial markers can easily be placed in 
an outpatient setting, more importantly, these markers allowed 
accurate delivery of RT while limiting acute toxicity.40 Investiga-
tors at the University of California San Francisco (UCSF) have 
shown that prostate markers provide an accurate guide such that 
treatments can be delivered within 2 mm, without the risk of seed 
migration.50 This progression has allowed the development in 
the field of image guided radiotherapy (IGRT) and 4D CRT. The 
“fourth dimension” in this setting refers to the impact of time 
on the position and/or shape of the target volume allowing tight 
margins that can be placed around the target tissues.
Monotherapy with radioactive seeds is preferably reserved 
for patients with low-risk disease, many groups are combining 
seed brachytherapy with EBRT for patients with intermediate 
to high-risk disease. The goal of this approach is to aim at 
higher tumor dose and better coverage of the target volume 
because of presumed extension of cancer cells beyond the 
prostate boundaries. The advantage of multi-modal RT is 
also seen in high-dose-rate brachytherapy in conjunction with 
IMRT over IMRT alone. The 3-year biochemical disease-free 
survival rates in high-risk patients treated with IMRT alone 
was 67% as opposed to 93% in the high dose rate (HDR) 
brachytherapy and IMRT group.51 The same benefit has 
also been shown in intermediate and high-risk patients who 
received 3DCRT with a single HDR brachytherapy implant 
over 3DCRT. The 5- and 7-year biochemical control rates 
for intermediate were 82.5% and 80.3%, respectively, for the 
combined group and 81.3% and 71%, respectively, for 3DCRT 
alone. In addition, there was minimal toxicity in patients with 
unfavorable CaP who underwent combination therapy.52
Stereotactic body radiotherapy is being rapidly deployed 
in the treatment of localized CaP. The prostate target is  usually 
localized in space using an external frame of  reference 
which can be related to the treatment machine. Stereotac-
tic positioning can be precise and as a result, stereotactic 
radiotherapy commonly employs higher doses per fraction 
and fewer fractions (hypofractionation) than conventional 
radiation. Stereotactic body radiotherapy typically consists 
of a total course of therapy comprising five or fewer treat-
ments. Many commercially available systems are currently 
used that typically incorporate some type of sophisticated 
image guidance and most also have patient immobilization 
devices (eg, CyberKnife® Robotic Radiosurgery System, 
Accuray, Inc., Sunnyvale, CA and many others). The utility 
of hypofractionation in the treatment of CaP is not conclusive 
and awaits the results of ongoing randomized trials to con-
firm any of the hypofractionation advantages over routinely 
administered (normofractionated) radiotherapy.53
Proton beam, or charged-particle beam, radiotherapy for 
CaP was first used at Massachusetts General Hospital in the 
1970s, but recently has received increased attention in press 
for the treatment of CaP. In theory, proton particles have better 
depth penetration than traditional photon or electron beam 
therapy and therefore, should deposit most of their energy 
near the tumor site rather than at the skin level. In addition, 
very little of the prescribed dose travels past the site of tumor, 
whereas, photons continue to deposit the dose of radiation in 
normal tissues beyond the tumor. This phenomenon is known 
as Bragg peak, where the pattern of delivery is localized with 
a sharp drop off past the projected site of delivery.54
In a phase II trial comparing the dosimetric characteristics 
of protons and IMRT, Vargas et al showed a decrease of 59% 
and 35% of the rectal and bladder dose, respectively.54 Proton 
beam therapy is expected to deliver biologically  equivalent 
doses more precisely and with less radiation-induced 
 morbidity than conventional photon radiation therapy. It is 
unclear whether the claimed high precision in dose delivery 
is beneficial, let alone necessary, for the treatment of CaP 
when compared to contemporary radiation techniques.
Cryotherapy
Cryotherapy has been used for surgical lesions since the 1850’s, 
when it was first introduced by Dr James Arnot.55 The American 
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Urologic Association (AUA) recognized cryotherapy first in 
1996 for the treatment of CaP. Although, only recently, the AUA 
has accepted cryosurgery as a  primary modality in treatment 
of localized CaP, published in Best Practice Statement on 
Cryosurgery for the Treatment of Localized Prostate Cancer.56 
Cryotherapy is currently  indicated in low-risk patients as an 
alternative to prostatectomy or radiotherapy, in higher-surgical-
risk patients as primary therapy, and in patients who have not 
responded to radiation therapy as a salvage procedure.
Historically, cryosurgery was associated with relatively 
high risks, such as urethral sloughing, rectal injury and  urinary 
fistulas. Major advances have occurred in the delivery of 
cryotherapy in the past 15 years. A significant development 
was the introduction of cryotherapy probes that use argon gas 
rather than liquid nitrogen. Argon rapidly cools the probe tip to 
-187°C (-304.6°F) and can be rapidly exchanged with helium 
at 67°C (152.6°F) for an active thawing phase, producing a 
faster response to operator input and significantly speeding 
2-cycle treatment.57 Moreover, argon-based probes have a 
much smaller diameter, thus permitting direct, sharp trans-
perineal insertion, facilitating more conformal cryosurgery.
Gland volume is an important factor: larger prostates may 
be more difficult to treat because of the difficulty in achieving a 
uniformly cold temperature throughout the gland. Neoadjuvant 
therapy for downsizing the gland may be considered in such 
patients, although there are no published studies on this topic.
With the newer generation of cryoprobe needles,  urethral 
and rectal warming catheters, real-time temperature  monitoring, 
the rates of complications have been drastically improved. 
In a review of current literature, the rates of  incontinence, 
urethral fistula, and urethral sloughing are reported to be 
2%–7%, 0%–2%, and 2%–6%, respectively.58,59,60 Han et al 
reported good outcomes in a series of 106 patients with 
only 3% incontinence requiring pads, 5% urge incontinence 
requiring no pads, 3.3% transient urinary retention, and 2.6% 
rectal pain.59 This demonstrates the relatively low complica-
tion profile of cryotherapy. Short of any head to head trials, 
in terms of being minimally invasive, the side-effect profile 
of cryoablation is comparable to EBRT and brachytherapy. 
Moreover, in a study by Hubosky et al at 18-month follow-up, 
cryosurgery patients had better urinary function compared with 
a series of brachytherapy patients, and this improvement was 
still present at 24 months.58 Robinson et al presented quality 
of life (QoL) outcomes from a single institution randomized 
trial  comparing EBRT with cryotherapy for localized CaP. 
Cryoablation patients reported lower urinary function scores 
(69.4 vs 90.7), similar bowel function, and lower sexual 
function scores (7.2 vs 32.9). At 36 months EBRT men had 
slightly lower urinary function scores but no difference in 
bowel function scores. The cryoablation patients had lower 
sexual function scores at 36 months (16 vs 36.7).61
One major downside to cryosurgery is the high risk of 
erectile dysfunction. This occurs primarily because the 
effective “kill zone” to ensure adequate prostatic  coverage 
extends to the periprostatic tissue, which includes the 
neurovascular bundle, necessary for erection. Hubosky 
et al reported that only 20% of the entire cohort was able 
return to baseline sexual function at 12-month followup.58 
This is similar to other published studies that report the 
incidence of ED after total gland cryosurgery, to be nearly 
90 percent of patients at 1 year of follow-up.59,60 Therefore, 
patients for whom preservation of erectile function is a 
high priority are probably less-than-ideal candidates.
One of the drawbacks of cryotherapy, similar to RT, is that 
post intervention monitoring of recurrent disease or failure of 
treatment can be difficult. Most commonly,  similar to post RT 
patients, PSA is followed but the  definition of biochemical 
failure is not universally defined. The two  definitions, ASTRO 
criteria and the Phoenix criteria, described in EBRT data are 
implemented in the cryotherapy literature. Others have used 
a strict PSA cutoff. However, the nadir PSA cutpoint that 
should represent the absence of cancer remains uncertain. 
Long-term retrospective data from Cohen et al reported 
10-year biochemical Disease Free Survival (bDFS) of 56.01% 
according ASTRO criteria and 62.36% using the Phoenix 
criteria (nadir plus 2 ng/mL). When stratified by risk groups 
(low, medium, and high), bDFS using the Phoenix criteria was 
80.56%, 74.16%, and 45.54%, respectively.62
Jones et al recently published the largest series of patients 
undergoing whole gland cryotherapy as primary treatment, 
all of whom were included in the Cryo On-Line Database 
(COLD) registry the largest cohort published regarding whole 
gland cryotherapy for localized CaP. The median pretreat-
ment PSA level was 6.8 ng/mL (mean, 9.6 ± 8.6 ng/mL), and 
various Gleason scores were represented (median, 7). The 
mean follow-up period was 24.4 ± 25.9 months. Applying the 
Phoenix definition to the data from men accumulated in that 
registry, 91 percent of men with low-risk, 78 percent of men 
with intermediate-risk, and 62 percent of men with high-risk, 
localized CaP experienced biochemical recurrence.63
The COLD registry is a multicenter collaboration, 
was developed and incorporates data from four academic 
 medical centers and 34 community urologists, so that con-
trol of the generation of cryosystem used and treatment 
protocols varied among different centers. This inherently 
weakens the data as there is no standardization in deliver-
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ing the treatment modality. More importantly, 49.5% of 
these men received hormone therapy prior to cryoablation, 
perhaps giving a false undetectable PSA.63 Regardless, 
published data from the COLD registry report 5-year bDFS 
of 77.1% using the ASTRO criteria and 72.9% using the 
Phoenix criteria. Using risk stratification, the 5-year bDFS 
was 84.7%, 73.4%, and 75.3% (ASTRO) and 91.1%, 78.5%, 
and 62.2% (Phoenix) for low-, medium-, and high-risk 
groups, respectively.63
As discussed earlier, incidence of ED is high in patients 
undergoing whole gland ablation. Although still in  experimental 
stages, focal cryoablation, or commonly coined term the “male 
lumpectomy” of the prostate is developing as a potential option 
for patients with unilateral, low-risk cancer. The goal behind 
Table 3 Comparison of some prostate cancer treatment options for localized disease
Treatment Benefits Limitations
Active surveillance/watchful  
waiting
• Avoids treatment of insignificant cancer 
•  Not risks of side effects from surgery  
or radiation
• Potential “anxiety” from not treating a diagnosed cancer 
•  Regular rectal exams, PSA testing with periodic/multiple  
biopsy to monitor
• Possibility that “window of curability” may be missed
Radical prostatectomy • Accurate pathologic staging 
•  Allows PSA to be more reliable marker  
of disease control
•  Trials demonstrate reduction in prostate  
cancer specific deaths
• Allows potential for nerve sparing procedure 
•  Long term outcome data available (for open  
radical prostatectomy)
•  Compared to radiation treatments, less issues  
with urinary frequency or urgency, rectal and  
bowel irritation
• Salvage possible with eBRT
• Surgical risks (infection, bleeding, reaction to anesthesia, etc) 
•  For laparoscopic/robotic technique: additional risk of  
intrabdominal injury or pneumoperitoneum related  
complications; limited long term outcome data at present
• Limited physical activity in recovery period (2–4 weeks) 
•  Post op complications of incontinence: 5%–20% (usually  
stress); erectile dysfunction: up to 50% at 5 years (with nerve  
preservation, may be improved by medical therapy); bladder  
neck contractures 1%–3%; lymphocele with retropubic 
approach; rare rectal injury
external beam radiation  
therapy (eBRT)  
(normofractionation)
• Avoids hospital stay and risk of surgery 
• Outpatient, limited impact on daily living 
• Long term cancer control reported 
•  Addition of hormonal therapy improved  
cancer control for high risk
• Incontinence rare (1%–2%) 
•  Urinary retention less common than with  
brachytherapy
• No post-treatment staging information 
• Daily treatments for 6–8 weeks 
• Fatigue may occur when treatment ends 
• erectile dysfunction: up to 50% at 5 years 
•  Bowel/rectal problems: 5%–10% (urgency, pain, diarrhea, or  
bleeding) but typically improve after treatment
• Bladder irritation: 5% (urinary frequency, urgency, discomfort) 
•  Salvage therapies limited or associated  
with high complication rate
Stereotactic body  
radiotherapy  
(hypofractionation)
•  “Convenient” outpatient treatments  
as short as five days
• Utility and side effect profile not well studied
Brachytherapy •  Minimal surgical risks, one time outpatient  
surgical procedure
• Best for low risk prostate cancer 
•  Delivers higher dose to prostate target,  
less to surrounding tissues
• Long term data available 
• Low rate of incontinence (1%–2%)
• Not useful for intermediate or high risk cancer 
• very small and very large glands (,20 cc, .80 cc) challenging 
• No final pathologic staging 
•  Less favorable option for men with intermediate- or high-risk  
disease
•  Not recommended for men with significant lower urinary  
tract symptoms
•  Urinary tract side effects (retention, urgency, frequency) more 
common than with other therapies
• eD outcomes similar to eBRT 
•  Salvage therapies limited or associated with high complication  
rate
Proton beam therapy •  Ability to deliver dose to prostate  
and avoid other structures
• Most costly infrastructure of all treatments 
•  No trials to demonstrate superiority over current radiation  
modalities
• Limited number of facilities 
Cryotherapy • One time treatment, often outpatient 
• Can be repeated 
• Allows for potential “focal” therapy
• No final pathology 
•  Side effect profiles can be difficult to manage, but improving  
with newer techniques
• High rate of eD for whole gland therapy
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focal therapy is to allow effective tumor ablation while sparing 
the neurovascular bundle. Onik et al reported their result of 
forty-eight patients with a mean follow-up of 4.5 years, who 
had focal cryoablation. Forty-five of 48 patients (94%) had 
stable PSAs, using the ASTRO criteria, with no evidence for 
cancer. Twenty-four patients who underwent routine biopsy 
had no evidence of disease.64
Focal cryoablation may therefore have a potential role for 
low-risk patients with unilateral disease on biopsy who are 
desirous of preserving erectile function. A study by Ward et al 
reviewed prostate specimens with unilateral positive prostate 
biopsy to characterize the location, volume and grade of each 
tumor focus, in determining if focal therapy templates could 
eradicate tumor burden. Despite only 17% of patients having 
a single focus of cancer, hemi-prostate treatment templates 
that would have been used in focal therapy would have suc-
cessfully treated all clinically significant prostate tumor foci 
in 81% of patients. Most out-of-field cancers were clinically 
insignificant tumors not identified by prostate biopsy (low-
volume, 0.5 mL; and low grade, Gleason score , or = 6).65 
Contemporary results of focal cryotherapy demonstrate 
high-potency rates of approximately 90%.64,66
Other treatment modalities
High intensity focused ultrasound (HIFU) is approved in the 
EU and in Canada but is not commercially available in the US. 
High dose rate radiation (HDR) employs temporary prostate 
implantation that requires a short hospital stay. It is usually done 
in combination with external beam radiation therapy. At present 
data is limited on this approach and the number of facilities that 
perform prostate cancer HDR in the US is limited.
Many elderly men with localized CaP receive only horm-
onal therapy. However, the benefit of hormonal  monotherapy 
(LHRH analogue alone, LHRH in  combination with antian-
drogens or with antiandrogens alone) in  localized cancer is 
not clear and can be associated with severe  toxicities in some 
men.67 Treatment guidelines do not recommend its use as a 
first-line therapy at earlier disease stages. Despite limited 
evidence to date for the impact on clinical outcomes, the use 
hormonal monotherapy therapy in patients with localized or 
locally advanced CaP has increased in many countries, most 
notably Japan.68 Hormonal therapy, either using LHRH ana-
logues alone or in combination with antiandrogens is currently 
controversial in localized CaP as a monotherapy and should 
not be used routinely until additional data is available.
Conclusion
As illustrated in this paper, there are numerous treatment 
options available for the management of localized CaP. At 
the present time, there is no single correct or “best” option 
for all men. The limited availability of head to head random-
ized trials makes picking the right treatment option more 
difficult. The trend for patients seeking multidisciplinary 
clinical consultations are often facilitated at cancer centers 
with a commitment to these patient centric efforts.69
As noted by the AUA, various factors must be taken into 
consideration when making a collective decision in the man 
with clinically localized CaP.70 Consideration for enrolling 
the patient in a randomized trial is always a top priority as we 
move the care of our patients ahead. The comparisons of the 
risks and benefits of treatments for localized CaP and AUA 
recommendations are summarized in Tables 3 and 4. Quality 
of life factors such as potency, urinary, or rectal bother should 
play an important role in any patient’s treatment decision and a 
detailed discussion of these specific issues is beyond the scope 
of this paper. A recent publication by Sanda, et al provides 
excellent objective data on the potential major  quality of life 
effects of primary CaP treatment.71
Outcomes for men with low risk disease treated by  radiation 
or surgery appear to have similar cancer outcomes out to at 
least 10–15 years. Perhaps, the younger patient with greater 
than ten year life expectancy may benefit from accurate staging 
and an undetectable PSA offered by RP. With high risk disease, 
adjuvant radiation administered as part of a multimodality 
 treatment plan following prostatectomy may improve biochemi-
cal recurrence and possibly overall survival. Radiation combined 
Table 4 Treatment options for localized prostate cancer based on guidelines from the American Urologic Association70
Risk classification Treatment options Notes
Low AS, IR, eBRT, RP, ww Review patient preferences on QOL issues  
High RT dose may decrease PSA recurrence 
ww inferior to RP
Intermediate IR, eBRT, RP, ww No data to support superiority  
Six month HT + RT
High eBRT, RP, ww Multimodal approach to treatment  
Adjuvant and concurrent HT with RT
Abbreviations: AS, active surveillance; IR, interstitial radiotherapy; EBRT, external beam radiotherapy; RP, radical prostatectomy; WW, watchful waiting.
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with hormonal therapy is currently considered standard of care 
for those men with high risk features who opt for external beam 
radiation therapy. A patient interested in one single minimally 
invasive intervention may seek brachytherapy or cryotherapy. 
Finally, a suitable patient for AS may choose this less invasive 
route to monitor his CaP. In the end, the treatment of CaP needs 
to be individualized for each patient, after weighing in the cur-
rent information available to each patient’s expectations, overall 
health and quality of life.
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